GE Healthcare Launches Cytiva Plus Cardiomyocytes - - BioPharm International

ADVERTISEMENT

GE Healthcare Launches Cytiva Plus Cardiomyocytes


PTSM: Pharmaceutical Technology Sourcing and Management
Volume 10, Issue 6

GE Healthcare introduces the Cytiva Plus, a high fidelity human heart cell model that is available in quantities compatible with screening for cardiotoxicity, enabling earlier and more confident prioritization of compounds.

The Cytiva Plus is cryopreserved in quantities to match a range of applications, which are ready-for-use in multi-electrode arrays, impedance, and high content analysis applications for compound safety profiling.

The cardiomyocytes are produced in a way that reflects native human heart cell development, without engineering techniques that could alter expression levels of relevant genes. This makes Cytiva Plus a reproducible biologically relevant cell model that supports the measurement of electrophysiological, structural and functional cell changes, and demonstrates expected pharmacological responses to reference compounds, the company reports.

Cytiva Plus is compatible with various detection platforms, enabling compound profiling based on multiple cardiotoxicity indications for more integrated risk assessment and mechanistic investigations.

Source: GE Healthcare

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Pfizer to Acquire Vaccines from Baxter
July 30, 2014
GSK Submits EU Regulatory Filing for Malaria Vaccine Candidate
July 29, 2014
Bristol-Myers Squibb and Ono Pharmaceutical Collaborate on Immunotherapies
July 28, 2014
FDA Accepts First Biosimilar Filing
July 24, 2014
Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
Author Guidelines
Source: PTSM: Pharmaceutical Technology Sourcing and Management,
Click here